PEACE-3 study: Enzalutamide and Ra-223 as First-Line Therapy for mCRPC

The combination of enzalutamide and Ra-223 as first-line therapy for patients with bone metastatic castration-resistant prostate cancer significantly improves rPFS. This improvement was supported by a significantly improved OS and also by a statistically significant improvement in time to next systemic treatment, Silke Gillessen concludes in this MEDtalk from ESMO 2024 in Barcelona.